Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
21 06 2022
Historique:
pubmed: 10 5 2022
medline: 24 6 2022
entrez: 9 5 2022
Statut: ppublish

Résumé

Genetic variation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of which Omicron is currently the predominant variant circulating worldwide. SARS-CoV-2 variants of concern/variants of interest (VOC/VOI) have evidence of increased viral transmission, disease severity, or decreased effectiveness of vaccines and neutralizing antibodies. Remdesivir (RDV [VEKLURY]) is a nucleoside analog prodrug and the first FDA-approved antiviral treatment of COVID-19. Here, we present a comprehensive antiviral activity assessment of RDV and its parent nucleoside, GS-441524, against 10 current and former SARS-CoV-2 VOC/VOI clinical isolates by nucleoprotein enzyme-linked immunosorbent assay (ELISA) and plaque reduction assay. Delta and Omicron variants remained susceptible to RDV and GS-441524, with 50% effective concentration (EC

Identifiants

pubmed: 35532238
doi: 10.1128/aac.00222-22
pmc: PMC9211395
doi:

Substances chimiques

Antiviral Agents 0
GS-441524 1BQK176DT6
remdesivir 3QKI37EEHE
Adenosine Monophosphate 415SHH325A
Adenosine K72T3FS567
Alanine OF5P57N2ZX

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0022222

Références

JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
PLoS Pathog. 2010 May 06;6(5):e1000896
pubmed: 20463816
Sci Transl Med. 2022 Feb 23;14(633):eabl8282
pubmed: 34968150
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Sci Transl Med. 2019 May 29;11(494):
pubmed: 31142680
PLoS Pathog. 2021 Jan 19;17(1):e1009226
pubmed: 33465137
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Sci Transl Med. 2022 May 4;14(643):eabm3410
pubmed: 35315683
J Biol Chem. 2020 May 15;295(20):6785-6797
pubmed: 32284326
Science. 2020 Jun 19;368(6497):1331-1335
pubmed: 32321856
PLoS Pathog. 2021 Sep 17;17(9):e1009929
pubmed: 34534263
Nat Protoc. 2021 Mar;16(3):1761-1784
pubmed: 33514944
Antiviral Res. 2021 Apr;188:105033
pubmed: 33549572
Antiviral Res. 2022 Feb;198:105246
pubmed: 35032523
J Biol Chem. 2022 Feb;298(2):101529
pubmed: 34953856
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Antiviral Res. 2022 Feb;198:105252
pubmed: 35085683
Cell Res. 2022 Mar;32(3):322-324
pubmed: 35058606
J Virol. 2005 Mar;79(6):3846-50
pubmed: 15731278
EClinicalMedicine. 2021 Jul 31;39:101064
pubmed: 34401689
Antiviral Res. 2022 Feb;198:105247
pubmed: 35033572
J Med Chem. 2021 Apr 22;64(8):5001-5017
pubmed: 33835812
PLoS One. 2013 Dec 10;8(12):e82849
pubmed: 24340062
Sci Transl Med. 2022 Apr 28;:eabo0718
pubmed: 35482820
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
J Med Chem. 2017 Mar 9;60(5):1648-1661
pubmed: 28124907
J Biol Chem. 2020 Nov 20;295(47):16156-16165
pubmed: 32967965
J Virol. 2008 Sep;82(17):8942-6
pubmed: 18562527
Emerg Microbes Infect. 2022 Dec;11(1):277-283
pubmed: 34951565
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
Antiviral Res. 2021 Aug;192:105122
pubmed: 34186107
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
J Med Chem. 2022 Feb 24;65(4):2785-2793
pubmed: 33523654
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Cell Rep. 2022 May 17;39(7):110829
pubmed: 35550680
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Emerg Microbes Infect. 2021 Dec;10(1):291-304
pubmed: 33538646
Nat Commun. 2020 Oct 15;11(1):5214
pubmed: 33060595
Cell. 2021 May 13;184(10):2587-2594.e7
pubmed: 33861950
Bioorg Med Chem Lett. 2012 Apr 15;22(8):2705-7
pubmed: 22446091
Cell Rep. 2021 Jul 27;36(4):109450
pubmed: 34289384
Science. 2022 Feb 11;375(6581):678-680
pubmed: 35040667
Nat Commun. 2021 Nov 5;12(1):6415
pubmed: 34741049
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
Cell. 2020 Sep 17;182(6):1560-1573.e13
pubmed: 32783916

Auteurs

Jared Pitts (J)

Gilead Sciences, Inc., Foster City, California, USA.

Jiani Li (J)

Gilead Sciences, Inc., Foster City, California, USA.

Jason K Perry (JK)

Gilead Sciences, Inc., Foster City, California, USA.

Venice Du Pont (V)

Gilead Sciences, Inc., Foster City, California, USA.

Nicholas Riola (N)

Gilead Sciences, Inc., Foster City, California, USA.

Lauren Rodriguez (L)

Gilead Sciences, Inc., Foster City, California, USA.

Xianghan Lu (X)

Gilead Sciences, Inc., Foster City, California, USA.

Chaitanya Kurhade (C)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.

Xuping Xie (X)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.

Gregory Camus (G)

Gilead Sciences, Inc., Foster City, California, USA.

Savrina Manhas (S)

Gilead Sciences, Inc., Foster City, California, USA.

Ross Martin (R)

Gilead Sciences, Inc., Foster City, California, USA.

Pei-Yong Shi (PY)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.

Tomas Cihlar (T)

Gilead Sciences, Inc., Foster City, California, USA.

Danielle P Porter (DP)

Gilead Sciences, Inc., Foster City, California, USA.

Hongmei Mo (H)

Gilead Sciences, Inc., Foster City, California, USA.

Evguenia Maiorova (E)

Gilead Sciences, Inc., Foster City, California, USA.

John P Bilello (JP)

Gilead Sciences, Inc., Foster City, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH